You searched for "allergy"
To montelukast or not to montelukast
Both histamine and cysteinyl leukotrienes play an important role in both seasonal allergic rhinoconjunctivitis (SARC) and asthma. A combination therapy against both was shown to give benefit both in vitro and in vivo. Authors wanted to test the efficacy of...
A trial of house dust mite sublingual tablet in children with allergic rhinitis
The house dust mite (HDM) is one of the commonest causative agents in allergic rhinitis (AR), affecting patients across all demographics. Recently, sublingual immunotherapy (SLIT) has been shown in clinical trials and meta-analysis to be effective compared to placebo in...
Omalizumab for CRSwNP: a monoclonal antibody
A prospective study from London, evaluating the response of chronic rhinosinusitis patients with nasal polyposis who were being treated with monoclonal antibody against IgE for severe allergic asthma. Thirteen patients were treated with Omalizumab, according to UK guidelines for their...
Outcomes in rhinosinusitis
This review goes through the various different ways of assessing outcomes and describes the pros, cons and limitations of each. The different methods are described in the context of guidelines in diagnosis and management and compared with other conditions such...
Prostaglandin versus leukotriene receptor-antagonists in treatment of seasonal allergic rhinitis RCT phase II
Seasonal allergic rhinitis is very common. Failure to control the disease with mono-therapy leads to dual therapy treatment with less compliance and reduced quality of life. A prostaglandin receptor antagonist (ONO-4053) showed some efficacy in controlling allergic rhinitis in animal...
Nasal nitric oxide – an inflammatory marker in paediatric allergic rhinitis?
Nasal nitric oxide (nNO) is mainly produced in the paranasal sinus mucosa and was shown in some studies to have increased expression in allergic rhinitis (AR). Although it represents a potential non-invasive tool for AR measurement, there remains no consensus...
Can we predict how much benefit patients will get from ESS with a novel monoclonal antibody
Mepolizumab (Nucala) is a humanised IgG1 monoclonal antibody that acts as an IL-5 antagonist. It has been shown to be highly effective in treating severe asthma. It is hypothesised that it will be effective for patients with recalcitrant CRSwNP. This...
Immunotherapy – could it be cheaper?
Immunotherapy is the only treatment for allergy to alter the disease course. Limited data exist on direct and indirect costs of subcutaneous (SCIT) and sublingual (SLIT) immunotherapy in America. This article assesses the cost effectiveness worldwide of the two immunotherapies....Chronic rhinosinusitis management: back to the future?
Immunology is a dim and distant medical school memory to many ENT surgeons, but the increasingly complex immunology of chronic rhinosinusitis is fascinating (honestly!). Medical management options in CRS no longer just involves saline and steroids, and we need to...
Rhinology and Skull Base Surgery – From the Lab to the Operating Room: an Evidence-based Approach
There have been many attempts to comprehensively address the topic of ‘Rhinology’, however Georgalas and Fokkens in their new book Rhinology and Skull Base Surgery – From the lab to the operating room: an evidence-based approach, have managed to deliver...
